JP2022516647A5 - - Google Patents
Info
- Publication number
- JP2022516647A5 JP2022516647A5 JP2021539465A JP2021539465A JP2022516647A5 JP 2022516647 A5 JP2022516647 A5 JP 2022516647A5 JP 2021539465 A JP2021539465 A JP 2021539465A JP 2021539465 A JP2021539465 A JP 2021539465A JP 2022516647 A5 JP2022516647 A5 JP 2022516647A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789347P | 2019-01-07 | 2019-01-07 | |
| US62/789,347 | 2019-01-07 | ||
| US201962823477P | 2019-03-25 | 2019-03-25 | |
| US62/823,477 | 2019-03-25 | ||
| US201962824164P | 2019-03-26 | 2019-03-26 | |
| US62/824,164 | 2019-03-26 | ||
| US201962855612P | 2019-05-31 | 2019-05-31 | |
| US62/855,612 | 2019-05-31 | ||
| PCT/US2020/012438 WO2020146290A1 (en) | 2019-01-07 | 2020-01-06 | A non-toxic cas9 enzyme and application thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516647A JP2022516647A (ja) | 2022-03-01 |
| JP2022516647A5 true JP2022516647A5 (https=) | 2023-01-19 |
| JPWO2020146290A5 JPWO2020146290A5 (https=) | 2023-01-19 |
Family
ID=71520905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539465A Pending JP2022516647A (ja) | 2019-01-07 | 2020-01-06 | 非毒性ｃａｓ９酵素およびその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210403922A1 (https=) |
| EP (1) | EP3908659A4 (https=) |
| JP (1) | JP2022516647A (https=) |
| CN (1) | CN113811611A (https=) |
| AU (1) | AU2020206997A1 (https=) |
| CA (1) | CA3125009A1 (https=) |
| GB (2) | GB2596660B (https=) |
| WO (1) | WO2020146290A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| EP4243608A1 (en) * | 2020-11-11 | 2023-09-20 | Leibniz-Institut für Pflanzenbiochemie (IPB) | Fusion protein for editing endogenous dna of a eukaryotic cell |
| AU2021409732A1 (en) * | 2020-12-23 | 2023-07-20 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
| EP4317549A4 (en) * | 2021-03-31 | 2025-03-26 | Ddbio. Co, Ltd., (Shang Hai) | Vector and method for screening functional antigen-binding protein |
| CN113481184A (zh) * | 2021-08-06 | 2021-10-08 | 北京大学 | 融合蛋白以及其使用方法 |
| EP4396340A4 (en) * | 2021-09-01 | 2025-09-24 | Univ Leland Stanford Junior | RNA-GUIDED GENOME RECOMBINATION AT THE KILOBASE SCALE |
| WO2023168235A2 (en) * | 2022-03-01 | 2023-09-07 | Crisp-Hr Therapeutics, Inc. | Systems and methods of gene editing |
| CN116286741A (zh) * | 2022-03-03 | 2023-06-23 | 清华大学 | 5’→3’核酸外切酶在基因编辑系统中的用途和基因编辑系统及其编辑方法 |
| EP4286401A1 (en) * | 2022-06-03 | 2023-12-06 | Technische Universität Dresden | Use of an artificial protein or of a nucleic acid encoding the artificial protein for providing a functional ribonucleoprotein complex |
| JP2025012122A (ja) * | 2023-07-12 | 2025-01-24 | 国立研究開発法人農業・食品産業技術総合研究機構 | 遺伝子組換えチョウ目昆虫 |
| WO2025137069A1 (en) * | 2023-12-18 | 2025-06-26 | University Of Maryland, Baltimore | Compositions and methods for enhanced genome editing using cas9 fusion proteins |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4357457B1 (en) * | 2012-10-23 | 2024-10-16 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| US9388430B2 (en) * | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US20150165054A1 (en) * | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| WO2016007604A1 (en) * | 2014-07-09 | 2016-01-14 | Gen9, Inc. | Compositions and methods for site-directed dna nicking and cleaving |
| EP3204496A1 (en) * | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| CA2963820A1 (en) * | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| US10155938B2 (en) * | 2015-04-14 | 2018-12-18 | City Of Hope | Coexpression of CAS9 and TREX2 for targeted mutagenesis |
| GB201510296D0 (en) * | 2015-06-12 | 2015-07-29 | Univ Wageningen | Thermostable CAS9 nucleases |
| US20170175140A1 (en) * | 2015-12-16 | 2017-06-22 | Regents Of The University Of Minnesota | Methods for using a 5'-exonuclease to increase homologous recombination in eukaryotic cells |
| US11274288B2 (en) * | 2016-02-16 | 2022-03-15 | Emendobio Inc. | Compositions and methods for promoting homology directed repair mediated gene editing |
| US9982267B2 (en) * | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| WO2018162702A1 (en) * | 2017-03-10 | 2018-09-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nuclease fusions for enhancing genome editing by homology-directed transgene integration |
-
2020
- 2020-01-06 GB GB2110538.2A patent/GB2596660B/en not_active Expired - Fee Related
- 2020-01-06 CN CN202080019483.3A patent/CN113811611A/zh active Pending
- 2020-01-06 EP EP20738520.4A patent/EP3908659A4/en not_active Withdrawn
- 2020-01-06 CA CA3125009A patent/CA3125009A1/en active Pending
- 2020-01-06 WO PCT/US2020/012438 patent/WO2020146290A1/en not_active Ceased
- 2020-01-06 AU AU2020206997A patent/AU2020206997A1/en not_active Abandoned
- 2020-01-06 JP JP2021539465A patent/JP2022516647A/ja active Pending
- 2020-01-06 GB GB2307873.6A patent/GB2616539B/en not_active Expired - Fee Related
-
2021
- 2021-07-06 US US17/368,369 patent/US20210403922A1/en not_active Abandoned
-
2023
- 2023-09-07 US US18/462,921 patent/US20240043851A1/en not_active Abandoned
- 2023-10-26 US US18/495,420 patent/US20240093207A1/en not_active Abandoned